Strasbourg, France, August 29th, 2008 - Transgene (Euronext Paris: FR0005175080) today announced results for the first half of 2008.
Highlights:
TG4001/R3484 for the treatment of precancerous lesions of the cervix: Transgene and Roche modify the clinical development plan to strengthen the product profile.
TG4010 for the treatment of non-small cell lung cancer: Positive results from the controlled phase IIb trial and presentation in June 2008 at the annual meeting of the American Society of Clinical Oncology.
TG4040 for the treatment of chronic hepatitis C: Promising preliminary results from Phase I trial show favourable tolerance profile and first indication of anti-viral activity.
TG1042 for the treatment of relapsing cutaneous B-cell lymphoma (CBCL): In the ongoing phase II trial, patient recruitment for the first stage is complete. In € million First half 2008 First half 2007 (excluding Roche partnership and capital increase) First half 2007 Revenues 5.5 1.8 24.7 Net cash expenditures (12.4) (14) 93.9 Net result (11.7) (14.2) 8.4 Cash and cash equivalents as of June 30, 2008: €98.9 million
“We have had a successful first half during which we have generated positive clinical results on projects in our pipeline and controlled expenses according to plan. We are making strong progress towards our goal of becoming a major integrated company providing patients with innovative therapies to treat cancer and infectious diseases,” Philippe Archinard, Chief Executive Officer of Transgene, commented.
Joey Whineray Consultant Capital MSL 81 Whitfield Street London W1T 4HG t. +44 (0) 20 7307 5337 f. +44 (0) 20 7307 5331
e: joanna.whineray@capitalmsl.com w: http://www.capitalmsl.com
